References
1. de Wit D, Guchelaar H-J, den Hartigh J, Gelderblom H, van Erp NP.
Individualized dosing of tyrosine kinase inhibitors: are we there yet?Drug Discov Today . 2015;20(1):18-36.
doi:10.1016/j.drudis.2014.09.007
2. Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug
monitoring of anticancer drugs part two–targeted therapies. Eur
J Cancer . 2014;50(12):2020-2036. doi:10.1016/j.ejca.2014.04.015
3. Klümpen H-J, Samer CF, Mathijssen RHJ, Schellens JHM, Gurney H.
Moving towards dose individualization of tyrosine kinase inhibitors.Cancer Treat Rev . 2011;37(4):251-260.
doi:10.1016/j.ctrv.2010.08.006
4. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema
ADR. Practical Guidelines for Therapeutic Drug Monitoring of Anticancer
Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets.Clin Pharmacokinet . 2014;53(4):305-325.
doi:10.1007/s40262-014-0137-2
5. Janssen JM, Dorlo TPCC, Steeghs N, et al. Pharmacokinetic Targets for
Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in
Pediatric Oncology. Clin Pharmacol Ther . 2020;0(0):cpt.1808.
doi:10.1002/cpt.1808
6. Riggs MM, Cremers S. Pharmacometrics and systems pharmacology for
metabolic bone diseases. Br J Clin Pharmacol .
2019;85(6):1136-1146. doi:10.1111/bcp.13881
7. Huang S-M, Abernethy DR, Wang Y, Zhao P, Zineh I. The utility of
modeling and simulation in drug development and regulatory review.J Pharm Sci . 2013;102(9):2912-2923. doi:10.1002/jps.23570
8. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and
pharmacodynamics of imatinib in a phase I trial with chronic myeloid
leukemia patients. J Clin Oncol . 2004;22(5):935-942.
doi:10.1200/JCO.2004.03.050
9. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in
patients with advanced cancer. Clin Cancer Res .
2009;15(12):4220-4227. doi:10.1158/1078-0432.CCR-08-2740
10. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and
antitumor activity of SU11248, a novel oral multitarget tyrosine kinase
inhibitor, in patients with cancer. J Clin Oncol .
2006;24(1):25-35. doi:10.1200/JCO.2005.02.2194
11. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A
therapeutic drug monitoring algorithm for refining the imatinib trough
level obtained at different sampling times. Ther Drug Monit .
2009;31(5):579-584. doi:10.1097/FTD.0b013e3181b2c8cf
12. Aspeslet LJ, LeGatt DF, Murphy G, Yatscoff RW. Effect of assay
methodology on pharmacokinetic differences between cyclosporine Neoral
and Sandimmune formulations. Clin Chem . 1997;43(1):104-108.
http://www.ncbi.nlm.nih.gov/pubmed/8990230.
13. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing
of tacrolimus prevents progressive systemic overexposure in renal
transplant recipients. Kidney Int . 2005;67(6):2440-2447.
doi:10.1111/j.1523-1755.2005.00352.x
14. Chatelut E, Bruno R, Ratain MJ. Intraindividual Pharmacokinetic
Variability: Focus on Small-Molecule Kinase Inhibitors. Clin
Pharmacol Ther . 2018;103(6):956-958. doi:10.1002/cpt.937
15. FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and
Biologics. Guidance for Industry.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics.
Published 2018. Accessed April 1, 2020.
16. Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N.
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards
Optimized Dosing. Clin Pharmacokinet . 2017;56(9):987-997.
doi:10.1007/s40262-017-0510-z
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response
evaluation criteria in solid tumours: Revised RECIST guideline (version
1.1). Eur J Cancer . 2009;45(2):228-247.
doi:10.1016/j.ejca.2008.10.026
18. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for
incorporating patient-reported outcomes into clinical comparative
effectiveness research in adult oncology. J Clin Oncol .
2012;30(34):4249-4255. doi:10.1200/JCO.2012.42.5967
19. National Cancer Institute. Common Terminology Criteria for Adverse
Events (CTCAE).
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Accessed March 31, 2020.
20. Atkinson TM, Ryan SJ, Bennett A V., et al. The association between
clinician-based common terminology criteria for adverse events (CTCAE)
and patient-reported outcomes (PRO): a systematic review. Support
Care Cancer . 2016;24(8):3669-3676. doi:10.1007/s00520-016-3297-9
21. Ferner R, Aronson J. Susceptibility to adverse drug reactions.Br J Clin Pharmacol . 2019;85(10):2205-2212. doi:10.1111/bcp.14015
22. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the
Development and Incorporation of Biomarker Studies in Early Clinical
Trials of Novel Agents. Clin Cancer Res . 2010;16(6):1745-1755.
doi:10.1158/1078-0432.CCR-09-2167
23. KKGT (Kwaliteitsbewaking Klinische Geneesmiddelanalyse en
Toxicologie). Oral oncolytics. http://kkgt.nl/?page_id=3661&lang=en.
Accessed March 31, 2020.
24. Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of
therapeutic concentration monitoring for imatinib dosage
individualization: results from a randomized controlled trial.Cancer Chemother Pharmacol . 2014;74(6):1307-1319.
doi:10.1007/s00280-014-2599-1
25. Gotta V, Bouchet S, Widmer N, et al. Large-scale imatinib
dose–concentration–effect study in CML patients under routine care
conditions. Leuk Res . 2014;38(7):764-772.
doi:10.1016/j.leukres.2014.03.023
26. Kloprogge F, Simpson JA, Day NPJ, White NJ, Tarning J. Statistical
power calculations for mixed pharmacokinetic study designs using a
population approach. AAPS J . 2014;16(5):1110-1118.
doi:10.1208/s12248-014-9641-4
27. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment
of dose proportionality: review of current approaches and proposal for a
practical criterion. Pharm Stat . 2009;8(1):38-49.
doi:10.1002/pst.326
28. Demetri GD, Wang Y, Wehrle E, et al. Imatinib Plasma Levels Are
Correlated With Clinical Benefit in Patients With
Unresectable/Metastatic Gastrointestinal Stromal Tumors. J Clin
Oncol . 2009;27(19):3141-3147. doi:10.1200/JCO.2008.20.4818
29. Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib
and its correlation with clinical response in the Tyrosine Kinase
Inhibitor Optimization and Selectivity Trial. Haematologica .
2012;97(5):731-738. doi:10.3324/haematol.2011.045666
30. Suttle AB, Ball HA, Molimard M, et al. Relationships between
pazopanib exposure and clinical safety and efficacy in patients with
advanced renal cell carcinoma. Br J Cancer .
2014;111(10):1909-1916. doi:10.1038/bjc.2014.503
31. Amengual JE, Johannet P, Lombardo M, et al. Dual Targeting of
Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215
and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res .
2015;21(20):4663-4675. doi:10.1158/1078-0432.CCR-14-3068
32. Westerdijk K, Desar IME, Steeghs N, Graaf WTA, Erp NP. Imatinib,
sunitinib and pazopanib: From flat‐fixed dosing towards a
pharmacokinetically guided personalized dose. Br J Clin
Pharmacol . 2020;86(2):258-273. doi:10.1111/bcp.14185
33. Groenland SL, van Eerden RAG, Verheijen RB, et al. Therapeutic Drug
Monitoring of Oral Anticancer Drugs. Ther Drug Monit .
2019;41(5):561-567. doi:10.1097/FTD.0000000000000654
34. de Wit D, van Erp NP, den Hartigh J, et al. Therapeutic Drug
Monitoring to Individualize the Dosing of Pazopanib. Ther Drug
Monit . 2015;37(3):331-338. doi:10.1097/FTD.0000000000000141
35. Lankheet NAG, Desar IME, Mulder SF, et al. Optimizing the dose in
cancer patients treated with imatinib, sunitinib and pazopanib. Br
J Clin Pharmacol . 2017;83(10):2195-2204. doi:10.1111/bcp.13327
36. Rousselot P, Johnson-Ansah H, Huguet F, et al. Personalized Daily
Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of
Molecular Responses in Patients with Chronic Myeloid Leukemia. Final
Results of the Randomized OPTIM Imatinib Study. Blood .
2015;126(23):133 LP - 133.
http://www.bloodjournal.org/content/126/23/133.abstract.
37. Lankheet NAG, Knapen LM, Schellens JHM, Beijnen JH, Steeghs N,
Huitema ADR. Plasma Concentrations of Tyrosine Kinase Inhibitors
Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer
Care. Ther Drug Monit . 2014;36(3):326-334.
doi:10.1097/FTD.0000000000000004
38. S Bouchet, P Rousselot, F Guilhot, J Guilhot, A Guerci, F Nicolini,
A Charbonnier, FX Mahon MM. Abstract CO-038 of the 19th Annual Meeting
of French Society of Pharmacology and Therapeutics, 36th
Pharmacovigilance Meeting, 16th APNET Seminar, 13th CHU CIC Meeting
21–23 April 2015 Caen, France. Fundam Clin Pharmacol .
2015;29(6):9-10. doi:10.1111/fcp.12104
39. Zuidema S, Desar IME, Erp NP, Kievit W. Optimizing the dose in
patients treated with imatinib as first line treatment for
gastrointestinal stromal tumours: A cost‐effectiveness study. Br J
Clin Pharmacol . 2019;85(9):1994-2001. doi:10.1111/bcp.13990
40. Ribba B, Dudal S, Lavé T, Peck RW. Model‐Informed Artificial
Intelligence: Reinforcement Learning for Precision Dosing. Clin
Pharmacol Ther . 2020;107(4):853-857. doi:10.1002/cpt.1777